Inicio › Cáncer de pulmón › Pensilvania › Pittsburgh
Ensayos clínicos de Cáncer de pulmón en Pittsburgh, PA
23 estudios para Cáncer de pulmón buscan participantes en centros de Pittsburgh y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
ReclutandoFase 3
- Bryn Mawr Hospital, Bryn Mawr · A 11 mi de distancia
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
ReclutandoFase 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutandoFase 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- y 11 más
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
ReclutandoFase 3
- Bryn Mawr Hospital, Bryn Mawr · A 11 mi de distancia
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Reclutando
- UPMC Hillman Cancer Center, Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ReclutandoFase 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · A 11 mi de distancia
- UPMC Hillman Cancer Center - Monroeville, Monroeville · A 11 mi de distancia
- y 1 más
A Registry for People With Lung Cancer
ReclutandoEstudio observacional
- ALLEGHENY HEALTH NETWORK (Data Collection Only), Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
ReclutandoFase 2
- Research Site, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
ReclutandoFase 2/3
- West Penn Allegheny Health, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ReclutandoFase 1/2
- Allegheny Health Network, Pittsburgh
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
ReclutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
ReclutandoFase 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
ReclutandoFase 3
- Allegheny Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
ReclutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
ReclutandoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
ReclutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
ReclutandoFase 2
- Allegheny General Hospital, Natrona Heights · A 19 mi de distancia
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
ReclutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutandoFase 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- y 11 más
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- y 9 más
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
ReclutandoEstudio observacional
- Allegheny Health Network, Pittsburgh
Detection of Genetic Markers of Lung Cancer
ReclutandoEstudio observacional
- Hillman Cancer Center, Pittsburgh
Más información sobre Cáncer de pulmón en MedlinePlus
Ensayos de Cáncer de pulmón en otras ciudades
- Houston, TX78 estudios
- Boston, MA62 estudios
- New York City, NY60 estudios
- Los Angeles, CA45 estudios
- Arlington, VA41 estudios
- Washington, DC41 estudios
- Chicago, IL41 estudios
- Nashville, TN40 estudios
- Baltimore, MD40 estudios
- St. Louis, MO39 estudios
- Columbus, OH37 estudios
- Philadelphia, PA36 estudios
Otros estudios en Pittsburgh
- Cáncer de pulmón de células no pequeñas48 estudios
- Cáncer (todos los tipos)41 estudios
- Cáncer de seno39 estudios
- Cáncer del colon y del recto32 estudios
- Cáncer metastásico31 estudios
- Melanoma31 estudios
- Cáncer de ovario30 estudios
- Cáncer de endometrio23 estudios
- Cáncer de próstata23 estudios
- Carcinoma de células escamosas de cabeza y cuello22 estudios
- Accidente cerebrovascular22 estudios
- Depresión22 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.